The Trump administration finalized a rule Tuesday barring Medicaid and the Children’s Health Insurance Program from paying for puberty blockers, cross-sex hormones, and surgical interventions on minors, a move that cuts off the federal funding pipeline for procedures the government now calls experimental and dangerous.
The Centers for Medicare and Medicaid Services issued the final rule after what HHS described as a “massive review of national and international research.” That review, CMS said, found “significant evidence gaps and serious safety concerns” surrounding gender-transition treatments for children. The rule takes effect October 13.
HHS Secretary Robert F. Kennedy, Jr. framed the decision in blunt terms. As Breitbart News reported, Kennedy stated:
“Today, we are ending federal taxpayer funding for sex-rejecting procedures on children. These interventions carry serious risks and can cause irreversible harm. The federal government will no longer use Medicaid and CHIP dollars to fund procedures that fail to meet the evidentiary standard our children deserve.”
CMS Administrator Dr. Mehmet Oz, who announced the rule at President Trump’s direction, echoed that position. Oz said children “deserve our protection, not experimental interventions that pose serious risks and convey no proven benefits.”
The final rule specifically targets three categories of treatment for minors: puberty-suppressing drugs, cross-sex hormones, and surgical interventions. CMS stated these procedures “can result in irreversible damage, including infertility, impaired sexual function, diminished bone density, altered brain development, and other lasting physiological effects.”
Children currently receiving hormone therapy funded through Medicaid or CHIP will not be cut off overnight. The rule includes a tapering-off period of up to six months. AP News reported that hormone treatment coverage would be phased out by April 2027 for those already receiving it.
Mental health services remain covered. CMS made that distinction explicit, stating the rule “does not apply to coverage for mental health services.”
That distinction matters. Critics of gender-transition procedures for minors have long argued that children experiencing gender distress need counseling and support, not irreversible medical interventions. The rule preserves the former while ending taxpayer funding for the latter.
How much federal money was flowing to these procedures? CMS Administrator Oz previously stated that at least $30 million in U.S. taxpayer dollars funded gender-transition procedures in 2023 alone, as the New York Post reported. The Washington Examiner placed estimates at over $250 million across a ten-year window.
Those figures help explain why Kennedy, in an earlier statement on the broader effort, called the practice something more pointed than bad policy. “This is not medicine, it is malpractice,” Kennedy said. “We’re done with junk science driven by ideological pursuits, not the well-being of children.”
The Washington Examiner noted that Kennedy signed a declaration finding that gender-transition procedures for minors “do not meet professionally recognized standards of care.” He also described the financial incentives at work in stark terms:
“Hospitals rake in millions of dollars by convincing boys and girls that a lifetime of off-label prescriptions for estrogen and testosterone blockers, chest reconstruction, surgeries, and more are the only way to achieve true happiness and belonging in life. It’s wrong.”
CMS cited the United Kingdom’s Cass Report, published in April 2024, as part of the evidence supporting its decision. That landmark review found serious gaps in the research base for pediatric gender-transition treatments and prompted the UK’s National Health Service to overhaul its approach.
Sweden moved to restrict gender treatments for minors as early as February 2023. CMS pointed to these international developments as evidence that its own assessment is “increasingly reflected” within the medical community worldwide.
Domestically, the agency cited recent policy shifts by the Society of Plastic Surgeons. And the trajectory extends beyond CMS. The Cleveland Clinic recently settled with the DOJ and agreed to halt transgender procedures on minors, one of what Trump described as “dozens of U.S. hospitals” that have already ended such practices.
Dr. Stanley Goldfarb, chairman of the medical watchdog group Do No Harm, called the action “a major step toward delivering a crippling blow to the child transgender industry.”
The FDA has also joined the effort. As National Review reported, the agency issued warning letters to 12 manufacturers of breast binders for illegally marketing products to children for gender dysphoria treatment. HHS also proposed reversing the Biden administration’s classification of gender dysphoria as a disability under Section 504 of the Rehabilitation Act of 1973.
The federal rule lands in a landscape already shaped by state-level action. At least 27 states have banned gender-transition treatments for minors, Fox News reported. But the legal battles are far from settled.
A Kansas judge blocked that state’s ban on gender-transition drugs for minors, prompting Attorney General Kris Kobach to vow an appeal. In Colorado, the state supreme court went further, ordering a children’s hospital to resume puberty blockers and cross-sex hormones for minors.
Those rulings illustrate the tension between federal policy and the judiciary. Whether the new CMS rule survives legal challenge remains an open question. No challenge had been announced at the time of the rule’s publication, but the pattern of litigation in this space makes one all but certain.
The rule also raises practical questions. The tapering provision addresses children currently on hormone therapy, but its application to minors already undergoing surgical interventions funded by Medicaid or CHIP is less clear. And the specific studies that comprised HHS’s “massive review” have not been publicly itemized.
Meanwhile, the broader cultural pressure campaign continues. A Michigan hospital recently paid $410,000 to a physician assistant fired for refusing transgender training on religious grounds, a reminder that the institutional machinery built around these procedures extends well beyond operating rooms.
President Trump used the announcement to draw a sharp political line ahead of November’s midterm elections. In a post to Truth Social, Trump wrote:
“Today, at my direction, Dr. Mehmet Oz announced that Medicaid will NO LONGER fund gender transition surgeries and hormones for minors. We are not going to pay for our innocent children to undergo these barbaric surgeries and practices, which result in unthinkable and irreversible harm to their young bodies.”
Trump credited his administration’s sustained pressure over “the past year and a half” for the wave of hospital reversals and urged voters to remember the issue at the ballot box.
The political calculation is straightforward. Polling has consistently shown that large majorities of Americans, including many Democrats, oppose surgical and hormonal gender-transition procedures for minors. The administration is betting that making taxpayers foot the bill for those procedures is a position no elected Democrat wants to defend in a competitive district.
Whether that bet pays off at the ballot box is a question for November. But the policy itself is now final, effective October 13, and it rests on a simple premise most Americans can understand: children who cannot legally vote, drink, or sign a contract should not have the federal government paying to alter their bodies in ways that cannot be undone.
If that’s controversial, the controversy says more about the institutions defending these procedures than about the rule ending their funding.
By signing up, you agree to receive newsletters and promotional content from American Frontline News and selected publications in the American Digest Media Network, operated with Patriot Mom Digest LLC, and you accept our Terms of Use and Privacy Policy. You may unsubscribe at any time.
By signing up, you agree to receive newsletters and promotional content from American Frontline News and selected publications in the American Digest Media Network, operated with Patriot Mom Digest LLC, and you accept our Terms of Use and Privacy Policy. You may unsubscribe at any time.